Adherence and persistence to prescribed medication therapy among Medicare Part D beneficiaries on dialysis: Comparisons of benefit type and benefit phase

Journal of Managed Care Pharmacy

Volumn 20, Issue 8, 2014, Pages 862-876

  Park, Haesuk ^a   Rascati, Karen L ^b   Lawson, Kenneth A ^b   Barner, Jamie C ^b   Richards, Kristin M ^b   Malone, Daniel C ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIMIMETIC AGENT; CINACALCET; PHOSPHATE BINDING AGENT; PRESCRIPTION DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE DERIVATIVE; SULFONYLUREA DERIVATIVE;

AGED; ARTICLE; DIABETES MELLITUS; DRUG COST; FEMALE; HEALTH INSURANCE; HEMODIALYSIS PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICARE; MEDICATION COMPLIANCE; PHARMACY; PRESCRIPTION; REIMBURSEMENT; ECONOMICS; HEALTH CARE COST; INSURANCE; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; UNITED STATES; ADULT; COHORT ANALYSIS; END STAGE RENAL DISEASE; HAZARD RATIO; OUTCOME ASSESSMENT; PATIENT COMPLIANCE;

AGED; FEMALE; HEALTH EXPENDITURES; HUMANS; INSURANCE BENEFITS; INSURANCE COVERAGE; MALE; MEDICARE; MEDICARE PART D; MEDICATION ADHERENCE; MIDDLE AGED; PRESCRIPTION DRUGS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84904902791     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.8.862     Document Type: Article

References (32)

1. Katzir Z, Boaz M, Backshi I, Cernes R, Barnea Z, Biro A. Medication apprehension and compliance among dialysis patients-a comprehensive guidance attitude. Nephron Clin Pract. 2010;114(2):c151-57.
2. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089-96.
3. Manley HJ, Garvin CG, Drayer DK, et al. Medication prescribing patterns in ambulatory haemodialysis patients: Comparisons of usrds to a large notfor- profit dialysis provider. Nephrol Dial Transplant. 2004;19(7):1842-48.
4. Lee A, Song X, Khan I, et al. Association of cinacalcet adherence and costs in patients on dialysis. J Med Econ. 2011;14(6):798-804.
5. Schmid H, Hartmann B, Schiffl H. Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res. 2009;14(5):185-90.
6. Hirth RA, Greer SL, Albert JM, Young EW, Piette JD. Out-of-pocket spending and medication adherence among dialysis patients in twelve countries. Health Aff (Millwood). 2008;27(1):89-102.
7. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004; 2004;291(19):2344-50.
8. Piette JD, Heisler M, Wagner TH. Cost-related medication underuse among chronically ill adults: the treatments people forgo, how often, and who is at risk. Am J Public Health. 2004;94(10):1782-87.
9. Schneeweiss S, Patrick AR, Pedan A, et al. The effect of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits. Health Aff (Millwood). 2009;28(2):w305-16.
10. Pedan A, Lu J, Varasteh LT. Assessment of drug consumption patterns for Medicare Part D patients. Am J Manag Care. 2009;15:323-27.
11. Zhang Y, Donohue JM, Newhouse JP, Lave JR. The effects of the coverage gap on drug spending: a closer look at Medicare Part D. Health Aff (Millwood). 2009;28(2):w317-25.
12. Hales JW, George S. How the doughnut hole affects prescription fulfillment decisions involving cardiovascular medications for Medicare Part D enrollees. Manag Care. 2010;19(12):36-44.
13. Polinski JM, Shrank WH, Huskamp HA, Glynn RJ, Liberman JN, Schneeweiss S. Changes in drug utilization during a gap in insurance coverage: an examination of the Medicare Part D coverage gap. PLoS Med. 2011;8(8):e1001075.
14. Fung V, Mangione CM, Huang J, et al. Falling into the coverage gap: Part D drug costs and adherence for medicare advantage prescription drug plan beneficiaries with diabetes. Health Serv Res. 2010;45(2):355-75.
15. Raebel MA, Delate T, Ellis JL, Bayliss EA. Effects of reaching the drug benefit threshold on Medicare members' healthcare utilization during the first year of Medicare Part D. Med Care. 2008;46(10):1116-22.
16. Zhang Y, Baik SH, Lave JR. Effects of Medicare Part D coverage gap on medication adherence. Am J Manag Care. 2013;19(6):e214-24.
17. St Peter WL. Chronic kidney disease and Medicare. J Manag Care Pharm. 2007;13(9 Suppl D):S13-18. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=13951.
18. U.S. Renal Data System. 2011 USRDS annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2011. Available at: http://www.usrds.org/2011/view/v1_00a_intro.asp. Accessed May 20, 2014.
19. Costantini L. Compliance, adherence, and self-management: is a paradigm shift possible for chronic kidney disease clients?. CANNT J. 2006;16(4):22-26.
20. Winkelmayer WC. Potential effects of the new Medicare Prospective Payment System on drug prescription in end-stage renal disease care. Blood Purif. 2011;31(1-3):66-69.
21. Feldman RL, Desmarais MP, Muller JS. Orals in the bundle: a policy framework. Clin J Am Soc Nephrol. 2013;8(6):1043-47.
22. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence:terminology and definitions. Value Health. 2008;11(1):44-47.
23. McHorney CA, Victor Spain C, Alexander CM, Simmons J. Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims. Clin Ther. 2009;31(11):2584-607.
24. Charlson ME, Charlson RE, Peterson JC, et al. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61(12):1234-40.
25. Hanley JA, Negassa A, Edwardes MD, Forrester JE. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol. 2003;157(4):364-75.
26. Curtin RB, Svarstad BL, Keller TH. Hemodialysis patients' noncompliance with oral medications. ANNA J. 1999;26(3):307-16.
27. Gincherman Y, Moloney K, McKee C, Coyne DW. Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients. Hemodial Int. 2010;14(1):68-72.
28. Jung K, Feldman R, McBean AM. Nonlinear pricing in drug benefits and medication use: the cost of statin compliance in Medicare Part D. Health Serv Res. 2014;49(3):910-28.
29. Kovas PJ, Perkins N, Nuschke E, Carroll N. How end-stage renal disease patients manage the Medicare Part D coverage. Health Soc Work. 2012;37(4):225-33.
30. Cronk A, Humphries TL, Delate T, Clark D, Morris B. Medication strategies used by Medicare beneficiaries who reach the Part D standard drugbenefit threshold. Am J Health Syst Pharm. 2008;65(11):1062-70.
31. Gu Q, Zeng F, Patel BV, Tripoli LC. Part D coverage gap and adherence to diabetes medications. Am J Manag Care. 2010;16(12):911-18.
32. Frankenfield DL, Howell BL, Wei II, Anderson KK. Cost-related nonadherence to prescribed medication therapy among Medicare Part D beneficiaries with end-stage renal disease. Am J Health Syst Pharm. 2011;68(14):1339-48.